ME INVESTOR NOTICE: Current 23andMe Holding Co. Shareholders are Notified to Contact BFA Law about Investigation into the Board of Directors (Nasdaq:ME)
23andMe Holding Co Class A ME
News
ME INVESTOR UPDATE: Shareholders of 23andMe Holding Co. are Alerted of Pending Investigation into the Company; Contact BFA Law if You Own Substantial Shares (Nasdaq:ME)
ME INVESTIGATION NOTICE: The Investigation into 23andMe Holding Co. is Ongoing – Contact BFA Law if You are a Current Shareholder (Nasdaq:ME)
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
ME SHAREHOLDER UPDATE: 23andMe Holding Co. is Under Investigation for Breaches of Fiduciary Duties; Current Shareholders are Urged to Contact BFA Law (Nasdaq:ME)
Barrack, Rodos & Bacine Is Investigating 23andMe Holding Co.
Barrack, Rodos & Bacine Is Investigating 23andMe Holding Co.
ME INVESTIGATION NOTICE: 23andMe Holding Co.’s Board of Directors is Being Investigated; Current Shareholders are Urged to Contact BFA Law (Nasdaq:ME)
ME INVESTOR UPDATE: 23andMe Shareholders are Notified to Contact BFA Law about Ongoing Investigation into the Company for Breaches of Fiduciary Duties (Nasdaq:ME)
Wolf Popper LLP is Investigating Whether the Offer to Acquire 23andMe Holding Co. By Its Controlling Shareholder Is Fair to the Minority Shareholders
ME STOCK ALERT: 23andMe Holding Co. Shareholders are Notified that an Investigation has been Initiated Against the Company’s Board of Directors and are Urged to Contact BFA Law (NASDAQ:ME)
23andMe's independent directors quit in clash with CEO over buyout plan
Independent Directors of 23andMe Resign from Board
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
23andMe Reports First Quarter Fiscal 2025 Financial Results
23andMe Special Committee responds to CEO’s take-private proposal
United States